



Souheil ZAYET ORCID iD: 0000-0003-3177-9806

## **Coronavirus disease 2019: new things to know!**

Correspondent author: **Souheil Zayet, MD**

Mail: souhail.zayet@gmail.com

Address: *Nord Franche-Comte* Hospital - Site de Belfort, Department of Infectious Diseases,

Belfort, 90016, FR

Tel number: +33772557117

Author 2: **Kadiane-Oussou, N'dri Juliette, MD**

Mail: kadianeoussou14@gmail.com

Address: *Nord Franche-Comte* Hospital - Site de Belfort, Department of Infectious Diseases,

Belfort, 90016, FR

Author 3: **Pierre-Yves Royer, MD**

Mail: pierre-yves.royer@hnfc.fr

Address: *Nord Franche-Comte* Hospital - Site de Belfort, Department of Infectious Diseases,

Belfort, 90016, FR

Author 4: **Lynda Toko, MD**

Mail: lynda.toko@hnfc.fr

Address: *Nord Franche-Comte* Hospital - Site de Belfort, Department of Infectious Diseases,

Belfort, 90016, FR

Author 5: **Vincent Gendrin, MD**

Mail: vincent.gendrin@hnfc.fr

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.25874.

This article is protected by copyright. All rights reserved.

Accepted Article

Address: *Nord Franche-Comte* Hospital - Site de Belfort, Department of Infectious Diseases,

Belfort, 90016, FR

Author 6: **Timothee Klopfenstein, MD**

Mail: timothee.klopfenstein@hnfc.fr

Address: *Nord Franche-Comte* Hospital - Site de Belfort, Department of Infectious Diseases,

Belfort, 90016, FR

*Souheil Zayet, N'dri Juliette Kadiane-Oussou, Pierre-Yves Royer, Lynda Toko, Vincent Gendrin, Timothée Klopfenstein*

*Infectious Disease Department, Nord Franche-Comté Hospital, France*

Dear Editor – We have read with interest the review of Feng et al. “Coronavirus Disease 2019 (COVID-19): What we know?”<sup>1</sup> which report the clinical features, diagnosis and treatment of the novel Coronavirus Disease 2019 (COVID-19).

In this review, the median age in the different studies ranging from 49 to 59 years, and more than half of patients were men. Nearly half of cases had one or more comorbidities, such as hypertension, diabetes, and cardiovascular disease. The main symptoms included fever, fatigue, dry cough, myalgia, and dyspnea. The uncommon symptoms included sputum production, headache, hemoptysis, and diarrhea. No otorhinolaryngological symptoms were described.

We conducted a study with COVID-19 patients resulting in similar findings; we emphasize that the most common symptoms are similar, but with a few other symptoms which are not reported by Feng et al. We conducted a retrospective study in the *Nord Franche-Comté* Hospital since a major French cluster of COVID-19 began on March, 1<sup>st</sup> 2020 in Mulhouse city (less than 30 miles from our hospital). Between

This article is protected by copyright. All rights reserved.

March, 1<sup>st</sup> and March, 13<sup>th</sup> 2020, we report the data about 62 patients infected with COVID-19. For each patient the diagnosis was confirmed by real-time RT-PCR on respiratory samples <sup>2</sup>.

Out of the 62 patients, 29 (47%) were hospitalized, the median age was 56 years [39-71], and 24 patients (39%) were men. Thirty-two (52%) had comorbidities, including cardiovascular disease (22[35%]), chronic obstructive pulmonary disease (11[18%], diabetes (10[16%]) and immunosuppression (2[3%]). Main symptoms (>50% of cases) were fever (> 38°C) for 47[76%] patients, fatigue (58[94%]), cough (50[81%]), headache (48[78%]), myalgia (38[61%]) and anosmia (32[52%]). Other symptoms (>30% of cases) were dysgeusia (30[48%]), rhinorrhea (30[48%]), diarrhea (24[39%]) and dyspnea (22[34%]). Nineteen patients (31%) had crackling sounds on pulmonary auscultation. In our study, one of our patients had acute encephalitis as initial presentation.

In comparison to the review of Feng et al. the main symptoms are similar: fever, fatigue, cough and myalgia. However, headache (three quarters of patients) and diarrhea (more than a third of patients) was more often notice in our study. Our main point is that anosmia and dysgeusia were present in half of the patients. To our knowledge, these otorhinolaryngological symptoms have never been described in COVID-19 beforehand. The influenza like illness (ILI) is nonspecific; however, anosmia and dysgeusia are not described associated with influenza <sup>3,4</sup>. Patient with ILI associated with anosmia and/or dysgeusia should lead clinicians to suspect a COVID-19. We wonder if there was invasion of the olfactory receptors or damage of the first cranial nerves in the nasal cavity cell membrane and/or central lesion; as described in post viral olfactory loss with other viruses <sup>5,6</sup>. As noticed above, 78% of our patients

Accepted Article

had headache and one patient had a presentation with acute encephalitis. The neuro-invasive mechanism of COVID-19 is poorly described. There are some arguments indicating that an alteration of the dopamine synthetic pathways is possibly involved in the pathophysiology of COVID-19 <sup>7</sup>. In all cases, there are increasing evidence that coronaviruses are not always confined to the respiratory tract and also invade the central nervous system inducing neurological diseases <sup>8,9</sup>.

## References

1. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? *J Med Virol*. March 2020. doi:10.1002/jmv.25766
2. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25(3). doi:10.2807/1560-7917.ES.2020.25.3.2000045
3. Cavallazzi R, Ramirez JA. Influenza and Viral Pneumonia. *Clin Chest Med*. 2018;39(4):703-721. doi:10.1016/j.ccm.2018.07.005
4. Paules C, Subbarao K. Influenza. *Lancet*. 2017;390(10095):697-708. doi:10.1016/S0140-6736(17)30129-0
5. Yamagishi M, Fujiwara M, Nakamura H. Olfactory mucosal findings and clinical course in patients with olfactory disorders following upper respiratory viral infection. *Rhinology*. 1994;32(3):113-118.
6. Kim YK, Hong S-L, Yoon EJ, Kim SE, Kim J-W. Central presentation of postviral olfactory loss evaluated by positron emission tomography scan: a pilot study. *Am J Rhinol Allergy*. 2012;26(3):204-208. doi:10.2500/ajra.2012.26.3759
7. Nataf S. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. *J Med Virol*. April 2020. doi:10.1002/jmv.25826
8. Li Y-C, Bai W-Z, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol*. February 2020. doi:10.1002/jmv.25728
9. Li Y, Bai W-Z, Hashikawa T. Response to Commentary on: “The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients.” *J Med Virol*. April 2020. doi:10.1002/jmv.25824

### **Contributors**

SZ, TK and JNKO collected the epidemiological and clinical data and processed statistical data. SZ and TK drafted the manuscript. LT, PYR and VG revised the final manuscript.

### **Declaration of interests**

All authors declare no competing interests. We thank all patients involved in the study and especially Dr Zahra Hajer for her help.